Published online Nov 15, 2016. doi: 10.4291/wjgp.v7.i4.300
Peer-review started: June 29, 2016
First decision: August 10, 2016
Revised: August 12, 2016
Accepted: September 13, 2016
Article in press: September 18, 2016
Published online: November 15, 2016
Processing time: 138 Days and 2.8 Hours
To investigate the bactericidal effects of calcium chelated N-acetylneuraminic acid-glycomacropeptide (CaG-NANA) against Helicobacter pylori (H. pylori).
For manufacture of CaG-NANA, calcium (Ca) was combined with glycomacropeptide (GMP) by chelating, and N-acetylneuraminic acid (NANA) was produced with Ca-GMP substrate by an enzymatic method. The final concentration of each component was 5% Ca, 7% NANA, 85% GMP, and 3% water. For in vitro study, various concentrations of CaG-NANA were investigated under the minimal inhibitory concentration (MIC). For in vivo study, CaG-NANA was administered orally for 3 wk after H. pylori infection. The levels of inflammatory cytokines in blood were analyzed by enzyme-linked immunosorbent assay and eradication of H. pylori was assessed by histological observation.
The time-kill curves showed a persistent decrease in cell numbers, which depended on the dose of CaG-NANA, and MIC of CaG-NANA against H. pylori was 0.5% in vitro. Histopathologic observation revealed no obvious inflammation or pathologic changes in the gastric mucosa in the CaG-NANA treatment group in vivo. The colonization of H. pylori was reduced after CaG-NANA treatment. The levels of interleukin (IL)-6, IL-1β, tumor necrosis factor-α, and IL-10 were also decreased by CaG-NANA.
CaG-NANA demonstrates effective anti-bactericidal activity against H. pylori both in vitro and in vivo.
Core tip: Calcium chelated N-acetylneuraminic acid-glycomacropeptide demonstrates effective anti-bactericidal activity against Helicobacter pylori both in vitro and in vivo.